Anistreplase
| Clinical data | |
|---|---|
| Trade names | Eminase |
| AHFS/Drugs.com | Micromedex Detailed Consumer Information |
| ATC code | |
| Pharmacokinetic data | |
| Elimination half-life | 90 minutes |
| Identifiers | |
| CAS Number | |
| DrugBank | |
| ChemSpider |
|
| UNII | |
| KEGG | |
| Chemical and physical data | |
| Molar mass | approx. 131 kg/mol |
| (verify) | |
Anistreplase is a
blood clots
in emergency situations.
Uses
Anistreplase is used to treat
blood clots in emergency situations such as myocardial infarction.[1] Early treatment gives better outcomes.[1]
Mechanism of action
Anistreplase is a complex of purified human
blood clots) to fibrin split products.[citation needed
]
History
Anistreplase has been developed by
Beecham under the brand name Eminase. It is also known as anisoylated plasminogen streptokinase activator complex (APSAC) after its components.[1][2][3]